R&D Pipeline
Pushing Scientific Boundaries
GC Genome is moving rapidly with robust R&D capabilities.
Our team are continuously pushing the boundaries of scientific knowledge to enhance the accuracy,
efficiency, and applicability of our clinical genomics technology.
| Product Candidate | R&D I | R&D 2 | Validation | Commercialization | |
|---|---|---|---|---|---|
| Liquid Biopsy (early detection) |
GCGLBx-CRC Colorectal Cancer early detection |
||||
| GCGLBx-LC Lung Cancer early detection |
|||||
| GCGLBx-HCC Hepatocellular carcinoma early detection |
|||||
| GCGLBx-PC Pancreatic Cancer early detection |
|||||
| GCGLBx-EC Esophageal Cancer early detection |
|||||
| GCGLBx-OC Ovarian Cancer early detection |
|||||
| Others | AI-NIPT non-invasive prenatal testing (NIPT) with machine learning analysis |
||||
| TNBC Classifier Prediction of disease-free survival after triple-negative breast cancer treatment |
|||||
| gHRD Prediction of PARP inhibitor response |
|||||
| tHRD Prediction of PARP inhibitor response using transcriptional mechanism |
|||||
| Gut Microbiome-HT Discovery Hypertension biomarkers using gut microbes |
|||||
